Aeterna Zentaris (NASDAQ:AEZS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research report sent to investors on Wednesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Performance

Shares of AEZS stock opened at $2.83 on Wednesday. The company has a market cap of $5.07 million, a P/E ratio of -0.19 and a beta of 1.55. The stock has a 50 day simple moving average of $2.88 and a two-hundred day simple moving average of $3.70. Aeterna Zentaris has a fifty-two week low of $3.96 and a fifty-two week high of $12.00.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.